GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
I

Incyte INCY · USD

Health Care · Biotechnology · US listing · 🇺🇸 United States

S&P 500

Compare

115.87

-1.64%

Close of 19 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Price performance

Chart by TradingView, with its own licensed prices

Incyte — daily INCY Delayed
Market value
$23.49bn
Last close × shares
Volume
1.2m
Shares, 19 Nov 2026
Price to earnings
19.2

About Incyte

From its filings with the US Securities and Exchange Commission

SEC filings

Incyte is based in Wilmington, Delaware and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker INCY. It is a member of the S&P 500. The SEC classifies its business as commercial physical & biological research. In the fiscal year to 31 December 2025, it reported revenue of $5.14bn and net income of $1.29bn. At that date it held total assets of $6.96bn and shareholders' equity of $5.17bn.

In its own words

Incyte is a global biopharmaceutical company engaged in the discovery, development and commercialization of proprietary therapeutics. Our global headquarters is located in Wilmington, Delaware, where we conduct discovery, clinical development and commercial operations. We also conduct clinical development and commercial operations from our European headquarters in Morges, Switzerland, and our other offices across Europe, as well as our Japanese headquarters in Tokyo and our Canadian headquarters in Montreal.

We are focused in three therapeutic areas that are defined by the indications of our approved medicines and the diseases for which our clinical candidates are being developed. These therapeutic areas are: Hematology, Oncology, and Inflammation and Autoimmunity (“IAI”).

Our hematology franchise includes four approved products, JAKAFI (ruxolitinib), ICLUSIG (ponatinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) and NIKTIMVO (axatilimab-csfr), as well as multiple clinical development programs.

Quoted from its 10-K, filed 10 Feb 2026. Read the filing on SEC.gov ↗

More about Incyte →

Latest on Incyte

Our reporting

Next results

9 Feb 2027

Due on 9 Feb 2027. Analysts expect earnings of 1.91 a share.

Other Health Care listings

Scenario calculator

Try your own numbers. This is arithmetic, not a forecast.

Interactive

Gain or loss

—

Return

—

Leaves out fees, taxes and financing.

Frequently asked questions

What is Incyte's ticker?

Incyte trades as INCY on its US listing, under ISIN US45337C1027.

What was Incyte's last closing price?

115.87 on 19 Nov 2026. The figure is in USD and is never converted.

When does Incyte next report results?

Results are expected on 9 Feb 2027, according to our data supplier.

Sources and methodology

Chart
TradingView
Close and company data
SEC filings and our data supplier
News
Our reporting

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.